



ELK OrthoBiologics

Elk OrthoBiologics Limited (“Elk”)

At least one-in-ten prosthetic hip and knee recipients develop aseptic loosening, a painful and debilitating bone condition resulting from long term inflammatory responses to microscopic wear particles generated by the prosthesis itself. The fast growing incidence of aseptic loosening is driven by the increasing use of prosthetic implants, with over 3 million hip and knee implants globally per annum (CAGR >6%), the ageing population and the obesity epidemic.

The only current treatment for aseptic loosening is major surgery (“revision surgery”) where the implanted prosthesis is replaced. As many patients with co-morbidities cannot undergo this treatment, there is a growing unmet medical need.

Elk is developing a minimally invasive gene therapy that allows the implanted prosthesis to be restabilised rather than removed, in order to improve walking ability and reduce pain. Importantly the approach avoids general anaesthesia and major surgery. A successful Phase 1 study in Europe in high risk patients with debilitating levels of hip loosening demonstrated the restoration of walking ability and pain reduction.

Elk is now preparing for a European Phase 2a clinical trial in 2017.

Elk is a Melbourne-based public unlisted biotechnology company. The Company is finalizing plans for an upcoming ASX listing in order to fully fund the Phase 2a clinical program. For more information please visit www.elkortho.com.